Exhibit 99.1

                    CardioDynamics Appoints Medical Director

    SAN DIEGO--(BUSINESS WIRE)--Jan. 8, 2004--CardioDynamics (Nasdaq:
CDIC), the innovator and leader of Impedance Cardiography (ICG)
technology, has appointed Neil W. Treister, MD, MBA, FACC, to fill the
newly-created position of Medical Director. This position will expand
CardioDynamics' physician outreach through medical education, clinical
publications and presentations worldwide.
    "This position will be instrumental in helping us drive clinical
adoption," stated Michael K. Perry, CEO of CardioDynamics. "With over
18 years of experience in the areas of cardiology and internal
medicine, and a strong business and teaching background, Dr. Treister
provides the clinical leadership to take us to the next level in
physician awareness and ICG utilization."
    Dr. Treister earned his medical degree from Stanford University in
1980 and is board certified in both Internal Medicine and
Cardiovascular Disease. He is an interventional cardiologist by
training and experience and his current clinical practice focuses on
preventive and consultative cardiology in both the office and hospital
settings. Dr. Treister also serves as Medical Director of Sharp
Healthcare's Cushman Wellness Center. He is on the National Pharmacy
and Therapeutics Committee for a national pharmacy benefits management
company and is on the Advisory Board of TechnaHealth, a disease
management company.
    Commenting on his appointment, Dr. Treister stated, "I am very
excited to join the CardioDynamics team and am looking forward to
working closely with the Company's medical group and senior management
in helping set the direction and strategy of our clinical programs."

    About CardioDynamics

    CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator
and leader of breakthrough medical technology called Impedance
Cardiography (ICG). The company's BioZ(R) Systems are being used by
leading physicians around the world to help battle the number one
killer of men and women -- cardiovascular disease. Partners include GE
Medical Systems Information Technologies and Philips Medical Systems.
The worldwide market potential for BioZ products is estimated to be $5
billion and an additional $800 million in recurring annual revenue for
sensors. For additional information or to request an investor package,
please refer to the company's Web site at www.cdic.com.

    Forward-Looking (Safe Harbor) Statement

    Except for the historical and factual information contained
herein, this press release contains forward-looking statements, such
as market size, potential, growth and penetration rates, the accuracy
of which is necessarily subject to uncertainties and risks including
the company's sole dependence on the BioZ product line, and various
uncertainties characteristic of early growth companies, as well as
other risks detailed in the company's filings with the SEC, including
its 2002 Form 10-K. The company does not undertake to update the
disclosures contained in this press release.


    CONTACT: CardioDynamics, San Diego
             Investor Relations:
             Bonnie Ortega, 888-522-2342 ext. 1005
             bortega@cardiodynamics.com
                 or
             Media Relations
             Irene Paigah, 888-522-2342 ext. 1012
             ipaigah@cardiodynamics.com